Postconditioning and Debio-025 Prevent LV Remodelling and Reduce Mortaility Following Acute Myocardial Infarction in Mice | Debio 025 | /

Home|Careers|Contact us

News

20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

Postconditioning and Debio-025 Prevent LV Remodelling and Reduce Mortaility Following Acute Myocardial Infarction in Mice

L. Gomez, H. Thibault, L. Argaud, O. Gateau-Roesch, J.M. Dumont, G. Vuagniaux, G. Derumeaux, M. Ovize

World Congress of Cardiology - Sept 2006 - Barcelona/Spain (Abstract + Poster)

pdf Poster